

## Special Issue

# Pharmacokinetics and Pharmacodynamics of Therapeutic Biologics

### Message from the Guest Editor

The Special Issue, “Pharmacokinetics and Pharmacodynamics of Therapeutic Biologics”, will focus on the pharmacokinetics and pharmacodynamics of biologics (proteins and peptides) such as therapeutic growth factors and antibody-based therapeutics, including monoclonal antibodies, bispecific antibodies, antibody–drug conjugates, fragment antibodies, etc. Therapeutic biologics are an important class of drugs used to treat a wide range of diseases. They have some unique pharmacokinetics (PK) and pharmacodynamics (PD) properties due to their molecular complexity. This Special Issue aims to provide an up-to-date overview of the latest research in this area, highlighting advances in our understanding of the PK and PD of therapeutic biologics, and identifying key areas for future research. This Special Issue is open for basic to clinical research, or a multidisciplinary approach, and will also cover original articles and reviews on the following topics:

- Determinants of PK and PD of biologics
- PK/PD and PBPK modeling
- Clinical pharmacology
- Novel technologies

---

### Guest Editor

Dr. Xiaoyu Yan

School of Pharmacy, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong

---

### Deadline for manuscript submissions

closed (30 September 2024)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

**Impact Factor 3.9**  
**CiteScore 6.8**  
**Indexed in PubMed**



[mdpi.com/si/168706](https://mdpi.com/si/168706)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).